The differential response to TSA between HF1/TP53/KRAS/MYC and HF1 cells underscores the importance of further investigations into the underlying epigenetic mechanisms and potential therapeutic implications for specific cancer subtypes. The gene discussed is KRAS; the disease is cancer.